Key result
TAVR is linked to ~13% fewer HF hospitalizations but increased all-cause admissions versus pre-TAVR.
Why the study?
Patients with severe aortic stenosis experience repeat hospitalizations for multiple conditions, prompting evaluation of the effect of TAVR on hospitalizations.
Does TAVR alter hospital resource utilization (hospitalizations and costs) in patients with severe aortic stenosis compared to the pre-TAVR period?
Cohort (n=15,324)
Yes
Does TAVR alter hospital resource utilization (hospitalizations and costs) in patients with severe aortic stenosis compared to the pre-TAVR period?
TAVR reduces heart failure hospitalizations and overall inpatient costs but is associated with increased all-cause, noncardiovascular, and bleeding hospitalizations in the year following the procedure.
TAVR may lower HF hospitalizations and costs in severe AS; leaves open net resource impact across broader real-world populations.
BACKGROUND Patients with severe aortic stenosis (AS) have repeat hospitalizations for multiple conditions. OBJECTIVES The purpose of this study was to assess the effect of transcatheter aortic valve replacement (TAVR) on hospitalizations in severe AS. METHODS Using data from the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) registry with linkage to Medicare claims, the authors examined rates of all-cause, cardiovascular, and noncardiovascular hospitalizations and hospital days, as well as inpatient costs in the year pre-TAVR and post-TAVR. Multivariable modeling was used to determine rate ratios of post-TAVR versus pre-TAVR hospitalizations and costs. RESULTS Among 15,324 patients at 328 sites with Medicare linkage undergoing TAVR, the median age was 84 years, the median Society of Thoracic Surgeons Predicted Risk of Mortality score was 7.0, and 61.1% patients underwent TAVR via transfemoral access. Post-TAVR, heart failure hospitalization rates and hospitalized days were reduced compared with pre-TAVR (rate ratio: 0.87 and 0.95 respectively; p < 0.01 for all). However, all-cause, noncardiovascular, and bleeding hospitalization rates and hospitalized days were increased (p < 0.01 for all). Post-TAVR hospitalizations were reduced the most among those with left ventricular ejection fraction <30%. Mean post-TAVR costs were reduced among all TAVR patients and among 1-year survivors (rate ratio: 0.95, p < 0.01; and 0.90; p < 0.01, respectively). CONCLUSIONS Patients had lower costs and fewer heart failure hospitalizations but more all-cause, noncardiovascular, and bleeding hospitalizations post-TAVR. Reduction in hospitalizations varied by specific patient subgroups, and thus, payors and providers seeking to reduce resource use may consider strategies designed to improve processes of care among patients with increased resource utilization post-TAVR as compared with pre-TAVR.
No takes yet. Share an insight, caveat, or question.
Vemulapalli et al. (2019) conducted a cohort in Severe aortic stenosis (n=15,324). Transcatheter aortic valve replacement (TAVR) vs. Pre-TAVR period was evaluated on Heart failure hospitalization rates (RR 0.87, p=<0.01). Transcatheter aortic valve replacement was associated with reduced heart failure hospitalizations (RR 0.87, p<0.01) but increased all-cause and noncardiovascular hospitalizations compared to pre-TAVR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: